



EHA2021 abstracts: What's hot in multiple myeloma and AL amyloidosis?

To help navigate the exciting content being presented at the EHA2021 Virtual Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and amyloid light-chain (AL) amyloidosis.



Click
the abstracts
to view



Scientific Education Support

Newly diagnosed multiple myeloma

S180	<u>DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE ± DARATUMUMAB AND ASCT: CASSIOPEIA PART 2 RESULTS</u>	Philippe Moreau
S183	<u>UPDATED INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL INVESTIGATING ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-KRD) IN FRONT-LINE TREATMENT OF HIGH-RISK MULTIPLE MYELOMA</u>	Katja Weisel
S184	<u>MEASURABLE RESIDUAL DISEASE (MRD) EVALUATION DURING IXAZOMIB (IXA) MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A LARGE ANALYSIS OF 1280 PATIENTS (PTS) ENROLLED IN TOURMALINE-MM3 AND -MM4</u>	Bruno Paiva
EP1010	<u>ANALYSIS OF A PHASE 2 MINIMAL RESIDUAL DISEASE (MRD)-ADAPTIVE TRIAL OF ELOTUZUMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ELO-KRD) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)</u>	Benjamin A Derman
EP1012	<u>ASSESSMENT OF TREATMENT RESPONSE BY MASS SPECTROMETRY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS FROM THE GEM2012MENOS65 CLINICAL TRIAL: COMPARISON WITH STANDARD SPEP/IFE</u>	Noemi Puig
LB1901	<u>OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY</u>	Thierry Facon
S185	<u>CIRCULATING TUMOR CELLS (CTC) ARE THE MOST RELEVANT DIAGNOSTIC BIOMARKER IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM)</u>	Juan-José Garcés

Relapsed/refractory multiple myeloma

S186	<u>UPDATES FROM ICARIA-MM, A PHASE 3 STUDY OF ISATUXIMAB (ISA) PLUS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE (PD) VERSUS PD IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)</u>	Aurore Perrot
S188	<u>ONCE WEEKLY SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (XKD) IN CARFILZOMIB NONREFRACTORY MULTIPLE MYELOMA (MM) PATIENTS</u>	Cristina Gasparetto
EP964	<u>UPDATED CARTITUDE-1 RESULTS OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA</u>	Saad Usmani
S190	<u>EFFICACY AND SAFETY OF THE BCMA-DIRECTED CAR-T CELL THERAPY, CILTACABTAGENE AUTOLEUCEL, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1–3 PRIOR LINES OF THERAPY: INITIAL RESULTS FROM CARTITUDE-2</u>	Mounzer Agha
S193	<u>TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 RESULTS</u>	Niels WCJ van de Donk
S192	<u>MAGNETISMM-1: PHASE 1 STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) TARGETED CD3-ENGAGING BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)</u>	Caitlin Costello
EP938	<u>ISB 1342: A FIRST-IN-CLASS CD38 T CELL ENGAGER FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA</u>	Mario Perro
S187	<u>IBERDOMIDE (IBER) IN COMBINATION WITH DEXAMETHASONE (DEX) AND DARATUMUMAB (DARA), BORTEZOMIB (BORT), OR CARFILZOMIB (CFZ) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)</u>	Sagar Lonial
EP987	<u>A PROSPECTIVE, NON-INTERVENTIONAL, MULTINATIONAL STUDY OF REAL-LIFE STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH ≥3 PRIOR LINES OF THERAPY: INTERIM DATA FROM LOCOMOTION</u>	Maria-Victoria Mateos

AL amyloidosis

S189

UPDATED RESULTS FROM PHASE 3 ANDROMEDA STUDY OF PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN AMYLOIDOSIS TREATED WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE PLUS SUBCUTANEOUS DARATUMUMAB

Efstathios Kastiris





Follow us on Twitter to keep up to date with the latest from the EHA2021 Virtual Congress!

@MM_Hub

#EHA2021

multiplemyelomahub.com